Criocore LLC

Criocore LLC, spun out of academic research at Harvard Medical School, specializes in bioprinted preclinical tissues to enhance drug testing and development, providing advanced models that replicate human biological responses for improved efficacy predictions. Founded in 2025 in Somerville, US, Criocore LLC focuses on bioprinted preclinical tissues. The company raised USD 200,000 in a pre-seed funding round from Antler on December 30, 2025. Criocore has engaged in one deal to date, reflecting its early-stage operations.

Criocore specializes in bioprinted preclinical tissues, positioning itself at the forefront of biomanufacturing technology. Their core offerings provide highly accurate models for drug testing and development, enhancing the efficiency of the preclinical research process. Bioprinted tissues replicate human biological responses, allowing pharmaceutical and biotech clients to predict drug efficacy and safety prior to clinical trials. Target clients include research institutions and companies primarily in North America and Europe, with plans to explore markets in the Asia-Pacific region to meet growing demands for advanced biomanufacturing.

Criocore generates revenue through direct B2B transactions with clients in the pharmaceutical and biotechnology sectors. Its revenue model is based on customized service agreements for specific research projects involving bioprinted tissues. Clients may enter contracts for tailored tissue types, creating arrangements that encompass both one-time purchases and ongoing projects, supported by tiered pricing plans based on tissue complexity and volume, promoting sustainable revenue growth and long-term relationships in the industry. Criocore plans to leverage the recent investment of USD 200,000 from Antler to support its growth initiatives, including the development of new bioprinted products aimed at enhancing drug testing capabilities.

The company targets expansion into the Asia-Pacific market by 2026 to capitalize on increasing biomanufacturing demand. These strategic moves aim to solidify Criocore's position in the biomanufacturing sector and broaden its client base.